[1]李丽梅,范嘉俊,何从新,等.敛疡汤灌肠联合参苓白术散加减口服治疗轻中度活动期溃疡性结肠炎临床研究[J].陕西中医,2025,46(10):1341-1346.[doi:DOI:10.3969/j.issn.1000-7369.2025.10.008]
　LI Limei,FAN Jiajun,HE Congxin,et al.Observation on the therapeutic effect of Lianyang decoction enema combined with modified oral administration of Shenling Baizhu powder in the treatment of mild to moderate active ulcerative colitis[J].,2025,46(10):1341-1346.[doi:DOI:10.3969/j.issn.1000-7369.2025.10.008]
点击复制

敛疡汤灌肠联合参苓白术散加减口服治疗轻中度活动期溃疡性结肠炎临床研究

《陕西中医》[ISSN:1000-7369/CN:61-1281/TN]

卷:
46
期数:
2025年10期
页码:
1341-1346
栏目:
临床研究
出版日期:
2025-10-05

文章信息/Info

Title:
Observation on the therapeutic effect of Lianyang decoction enema combined with modified oral administration of Shenling Baizhu powder in the treatment of mild to moderate active ulcerative colitis
作者:
李丽梅1; 范嘉俊1; 何从新2; 张丹3
（1.江苏大学附属昆山医院 昆山市第一人民医院，江苏 昆山 215300；2.昆山市第三人民医院，江苏 昆山 215300；3.江苏省中医院，江苏 南京 210029）
Author(s):
LI Limei1; FAN Jiajun1; HE Congxin2; ZHANG Dan3
(1.Kunshan Hospital Affiliated to Jiangsu University,the First People’s Hospital of Kunshan,Kunshan 215300,China;2.The Third People’s Hospital of Kunshan，Kunshan 215300,China;3.Jiangsu Provincial Hospital of Traditional Chinese Medicine,Nanjing 210029,China)
关键词:
活动期溃疡性结肠炎; 敛疡汤; 参苓白术散; 改良Mayo活动指数; 复发
Keywords:
Active ulcerative colitis; Lianyang decoction; Shenling Baizhu power; Modified Mayo Activity Index; Recrudescence
分类号:
R 516.1
DOI:
DOI:10.3969/j.issn.1000-7369.2025.10.008
文献标志码:
A
摘要:
目的：观察探讨轻中度活动期溃疡性结肠炎（UC）应用敛疡汤灌肠联合口服参苓白术散加减治疗的疗效。方法：回顾性分析轻中度活动期UC患者80例，按照患者意愿和入院顺序分为三组，A组26例（西药+口服参苓白术散加减+敛疡汤灌肠），B组27例（西药+口服参苓白术散加减），C组27例（西药），比较三组治疗总有效率、复发率及不良反应率，并比较三组治疗前后的中医证候积分、炎性指标、血清学指标、改良Mayo活动指数水平。结果：A、B组治疗后证候积分、血清白介素-6（IL-6）、C反应蛋白（CRP）、肿瘤坏死因子-α（TNF-α）、红细胞沉降率（ESR）、血小板（PLT）、D-二聚体（D-D）水平及改良Mayo活动指数的排便次数、便血、黏膜表现及总分均低于C组（P＜0.05）；IL-10水平高于C组（P＜0.05）；A组改善水平明显于B组（P＜0.05）。三组临床治疗效率中以A组最优(96.15%)，B组次之(88.89%)，C组最低(66.67%)，A组明显高于B、C组（P＜0.05）；A、B组间比较差异无统计学意义（P＞0.05）；三组复发率中以A组最低(3.85%)，B组次之(11.11%)，C组最高(37.04%)，A组明显低于B、C组（P＜0.05）；A、B组间比较差异无统计学意义（P＞0.05）。三组组间不良反应率比较差异无统计学意义（P＞0.05）。结论：轻中度活动期UC患者应用敛疡汤灌肠联合口服参苓白术散加减治疗的疗效确切，能有效改善症状，减轻炎症反应，促病情转归，减少复发。
Abstract:
Objective:To observe and explore the therapeutic effect of Lianyang decoction enema combined with oral administration of modified Shenling Baizhu powder on mild to moderate active ulcerative colitis (UC).Methods:Retrospective analysis of 80 patients with mild to moderate active UC,based on patient wishes and admission order,divided into three groups,group A consisted of 26 cases (Western medicine+oral modified Shenling Baizhu powder+Lianyang decoction enema),group B consisted of 27 cases (Western medicine+oral modified Shenling Baizhu powder),and group C consisted of 27 cases (Western medicine).The treatment efficiency,recurrence rate,and adverse reaction rate of the three groups were compared,and the TCM syndrome scores,inflammatory indicators,serological indicators,and modified Mayo activity index levels of the three groups before and after treatment were compared.Results:After treatment,the syndrome score,serum interleukin-6 (IL-6),C-reactive protein (CRP),tumor necrosis factor alpha (TNF-α),erythrocyte sedimentation rate (ESR),platelet count (PLT),D-dimer (D-D) levels,modified Mayo activity index defecation frequency,fecal blood,mucosal manifestations,and total score of groups A and B were lower than those of group C (P<0.05).The level of IL-10 was higher than that of group C (P<0.05);the improvement level of group A was significantly higher than that of group B (P<0.05).Among the three clinical treatment groups,group A had the best treatment efficiency of 96.15%,followed by group B at 88.89%,and group C at 66.67% had the lowest treatment efficiency.Group A was significantly higher than groups B and C (P<0.05);there was no statistically significant difference between group B (P>0.05).Among the three groups,group A had the lowest recurrence rate of 3.85%,followed by group B at 11.11%,and group C at 37.04% had the highest recurrence rate,group A was significantly lower than groups B and C (P<0.05).There was no statistically significant difference between group B (P>0.05).The incidence of adverse reactions between the three groups was not statistically significant (P>0.05).Conclusion:The application of Lianyang decoction enema combined with oral administration of modified Shenling Baizhu power has a definite therapeutic effect on mild to moderate UC patients.It can effectively improve symptoms,alleviate inflammatory reactions,promote disease progression,reduce recurrence.

参考文献/References:

[1]张艳,龚家顺,梁景星.美沙拉嗪联合益生菌对轻中度溃疡性结肠炎患者炎症因子及肠黏膜屏障功能的影响[J].临床消化病杂志,2024,36(1):22-26.
[2]黄华,马俊杰,华秋雯,等.柔肝健脾法联合美沙拉嗪灌肠液治疗远端型溃疡性结肠炎肝郁脾虚证的临床研究[J].国际中医中药杂志,2024,46(4):444-450.
[3]王福忠.参苓白术散加减辅治溃疡性结肠炎临床观察[J].实用中医药杂志,2022,38(9):1561-1563.
[4]吴开春,梁洁,冉志华,等.炎症性肠病诊断与治疗的共识意见（2018年·北京）[J].中国实用内科杂志,2018,38(9):796-813.
[5]中华中医药学会脾胃病分会.溃疡性结肠炎中医诊疗专家共识意见(2017)[J].中华中医药杂志,2017,32(8):3585-3589.
[6]国家食品药品监督管理总局.中药新药临床研究指导原则（试行）[M].北京：中国医药科技出版社，2002：122.
[7]中华中医药学会脾胃病分会．消化系统常见病消化性溃疡中医诊疗指南(基层医生版)[J].中华中医药杂志,2019,34(10):4721-4726．
[8]张玉洁,梁洁,吴开春.炎症性肠病诊断与治疗的共识意见(2018 年,北京)溃疡性结肠炎部分解读[J].中华消化杂志,2018,38(5):312-314.
[9]杨琴.双歧杆菌乳杆菌三联活菌片联合美沙拉嗪和肠炎宁胶囊治疗溃疡性结肠炎的效果及安全性分析[J].反射疗法与康复医学,2024,5(4):180-182,190.
[10]黄洪涛,赵莉,赵红红,等.美沙拉嗪联合中药保留灌肠治疗溃疡性结肠炎疗效观察[J].中国肛肠病杂志,2024,44(3):43-45.
[11]李丽梅,王永强.参苓白术散联合美沙拉嗪治疗溃疡性结肠炎临床观察[J].西部中医药,2021,34(10):124-126.
[12]李川,张其慧,杨蓓,等.清肝敛疡汤治疗肝胃郁热型幽门螺杆菌阳性消化性溃疡疗效观察[J].现代中西医结合杂志,2022,31(11):1476-1481.
[13]刘慧泽,周青,王包晟,等.黄葵敛疡汤治疗轻中度溃疡性结肠炎患者101例回顾性分析[J].辽宁中医杂志,2022,49(2):75-77.
[14]谢天阳,卢灿省.参苓白术散合肾气丸加味方联合美沙拉嗪栓对脾肾阳虚型溃疡性结肠炎的疗效观察[J].中医药临床杂志,2023,35(11):2212-2216.
[15]刘慧泽.黄葵敛疡汤治疗溃疡性结肠炎疗效观察及其作用机制研究[D].南京:南京中医药大学,2021.
[16]冯丽谦.敛疡汤保留灌肠治疗溃疡性直肠炎的临床疗效观察[J].中国研究型医院,2019,6(6):38-42.
[17]姜丽,张文彤,肖彤,等.参苓白术散抗溃疡性结肠炎的物质基础、作用机制及安全性评价[J].武汉大学学报(理学版),2024,70(2):236-252.
[18]邓永文,张全辉,陈教华,等.基于炎症反应研究参苓白术散加减方治疗溃疡性结肠炎的药效及作用机制[J].中国老年学杂志,2024,44(4):902-906.
[19]张玉佩.基于肠道微环境探讨参苓白术散对NAFLD大鼠TLR4/NLRP3信号通路作用的分子机制[D].广州:暨南大学,2018.
[20]张全辉,邓永文,周毛生,等.参苓白术散加减对溃疡性结肠炎患者IL-6、IL-10和TNF-α的影响[J].药品评价,2022,19(17):1054-1058.
[21]王辉钦,段莹莹,杨彦平,等.基于网络药理学探究地锦草防治溃疡性结肠炎的作用机制[J].中国畜牧兽医,2024,51(5):2154-2168.
[22]陈钰凤,范明,马玉婷.基于网络药理学的火炭母、凤尾草治疗溃疡性结肠炎的潜在机制研究[J].中国中医药图书情报杂志,2023,47(6):59-64.
[23]唐苇鸿,沈洪.基于网络药理学探讨茜草治疗溃疡性结肠炎的作用机制[J].中医临床研究,2021,13(31):5-11.
[24]杨乐天,杨晨,颜晓飞,等.鱼腥草总黄酮对小鼠结肠炎防治作用的研究[J].药学研究,2022,41(5):287-291,315.
[25]张立宏,张声生,谭海成,等.基于网络药理学研究黄连-黄柏药对治疗溃疡性结肠炎的作用机制[J].世界中医药,2022,17(2):147-151,157.
[26]姜爱雯,杜佩珊,蒲洁琨,等.葛根地榆紫草汤组方治疗溃疡性结肠炎的疗效及对炎症因子的影响[J].中国药物与临床,2020,20(3):341-343.

备注/Memo

备注/Memo:
国家自然科学基金资助项目（81904203）；江苏省昆山市重点研发计划（社会发展）指导性项目（KSZ2210）
更新日期/Last Update: 2025-10-10